Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) and Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Syndax Pharmaceuticals and Aligos Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Syndax Pharmaceuticals | 1 | 0 | 10 | 0 | 2.82 |
| Aligos Therapeutics | 1 | 0 | 5 | 1 | 2.86 |
Syndax Pharmaceuticals currently has a consensus price target of $42.30, indicating a potential upside of 140.89%. Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 653.42%. Given Aligos Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Syndax Pharmaceuticals.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Syndax Pharmaceuticals | $172.35 million | 9.03 | -$285.42 million | ($2.51) | -7.00 |
| Aligos Therapeutics | $31.52 million | 1.01 | -$24.19 million | ($7.30) | -0.70 |
Aligos Therapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Syndax Pharmaceuticals and Aligos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Syndax Pharmaceuticals | -87.52% | -372.94% | -39.11% |
| Aligos Therapeutics | -241.01% | -160.72% | -92.30% |
Institutional and Insider Ownership
60.4% of Aligos Therapeutics shares are held by institutional investors. 4.8% of Syndax Pharmaceuticals shares are held by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility and Risk
Syndax Pharmaceuticals has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500.
Summary
Aligos Therapeutics beats Syndax Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
About Aligos Therapeutics
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
